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Parkinson’s disease (PD) is mainly driven by dopaminergic neuronal degeneration
in the substantia nigra pars compacta accompanied by chronic neuroinflammation.
Despite being mainly sporadic, approximately 10% of all cases are defined as heritable
forms of PD, with mutations in the leucine-rich repeat kinase (LRRK2) gene being the
most frequent known cause of familial PD. MicroRNAs (miRNAs or miRs), including
miR-335, are frequently deregulated in neurodegenerative diseases, such as PD.
Here, we aimed to dissect the protective role of miR-335 during inflammation and/or
neurodegenerative events in experimental models of PD. Our results showed that
miR-335 is significantly downregulated in different PD-mimicking conditions, including
BV2 microglia cells stimulated with lipopolysaccharide (LPS) and/or overexpressing
wild-type LRRK2. Importantly, these results were confirmed in serum of mice injected
with 1-methyl-1-4-phenyl-1,2,3,6-tetrahydripyridine hydrochloride (MPTP), and further
validated in patients with idiopathic PD (iPD) and those harboring mutations in LRRK2
(LRRK2-PD), thus corroborating potential clinical relevance. Mechanistically, miR-335
directly targeted LRRK2 mRNA. In the BV2 and N9 microglia cell lines, miR-335 strongly
counteracted LPS-induced proinflammatory gene expression, and downregulated
receptor interacting protein 1 (RIP1) and RIP3, two important players of necroptotic
and inflammatory signaling pathways. Further, miR-335 inhibited LPS-mediated ERK1/2
activation. LRRK2-Wt-induced proinflammatory gene expression was also significantly
reduced by miR-335 overexpression. Finally, in SH-SY5Y neuroblastoma cells, miR-
335 decreased the expression of pro-inflammatory genes triggered by α-synuclein. In
conclusion, we revealed novel roles for miR-335 in both microglia and neuronal cells that
strongly halt the effects of classical inflammatory stimuli or LRRK2-Wt overexpression,
thus attenuating chronic neuroinflammation.
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INTRODUCTION
Parkinson’s disease (PD) is the second most common
neurodegenerative disorder worldwide, mainly instigated
by dopaminergic neurodegeneration in the substantia nigra pars
compacta (Poewe et al., 2017). The etiology of PD is complex and
involves chronic neuroinflammation, mitochondrial dysfunction
and oxidative stress (Poewe et al., 2017). Even though mostly
sporadic, about 10% of all cases are currently estimated to be
related to monogenic forms of PD (Henn et al., 2005; Poewe et al.,
2017). Pathogenic mutations in the leucine-rich repeat kinase 2
(LRRK2) gene are the most frequent known cause of monogenic
PD and are usually associated with a toxic gain-of-function of
LRRK2 kinase activity (Zimprich et al., 2004; Healy et al., 2008).
Importantly, the most frequent LRRK2 mutation, G2019S, can
be relatively common depending on the ethnic group, with
frequencies of 35.7% in sporadic and 42% in familial cases, in
specific populations (Mata et al., 2006; Healy et al., 2008).
Although the role of LRRK2 is still not completely understood,
LRRK2 pathogenic mutations are associated with dopaminergic
neuronal cell death, inflammatory responses, and oxidative
damage (Mata et al., 2006; Tsika and Moore, 2012). For
instance, LRRK2 seems to be involved in the regulation of
survival/inflammatory signaling pathways, such as mitogen-
activated protein kinase (MAPK) pathways, whose activation
may eventually lead to neuronal death (Chen et al., 2012).
Interestingly, it has also been suggested that, in specific
conditions, wild-type (wt) LRRK2 overexpression may protect
SH-SY5Y cells from death, by selectively activating ERK1/2
signaling (Liou et al., 2008). Moreover, an exacerbation of
LRRK2 levels in different immune cells, such as microglia or
macrophages, has been reported in response to inflammatory
stimuli, such as lipopolysaccharide (LPS) or interferon-γ (IFN-γ),
thereby perpetuating inflammation (Gardet et al., 2010; Gillardon
et al., 2012). The discoveries that both pharmacological and
genetic inhibition of LRRK2 can be neuroprotective in preclinical
models of PD (Chan and Tan, 2017; West, 2017; Zhao et al., 2017;
Chen et al., 2018) have placed LRRK2 at the center of disease
modifying PD strategies. In addition, recent findings also suggest
that LRRK2 plays a role in the pathogenesis of PD, indicating that
LRRK2-targeted therapies might, therefore, be beneficial in both
subtypes of PD (Tolosa et al., 2020).
Throughout the years, several experimental models have been
developed to mimic PD, including the systemic administration of
animals with 6-hydroxydopamine (6-OHDA) and 1-methyl-1-4-
phenyl-1,2,3,6-tetrahydripyridine hydrochloride (MPTP) (Dauer
and Przedborski, 2003). However, the neurotoxin MPTP has
been the most widely used to mimic PD-associated nigrostriatal
degeneration, since it can be systemically administered and
human exposure to MPTP induces severe parkinsonism
(Meredith and Rademacher, 2011; Langston, 2017).
MicroRNA (miRNA or miR) dysregulation can also contribute
to the development and progression of a wide variety of human
diseases, including PD, where miRNAs have been associated with
neuroinflammation (Martins et al., 2011; Miñones-Moyano et al.,
2011; Patil et al., 2019). In this regard, miR-335 has recently
been involved in PD. The results are somehow contradictory,
with some authors suggesting that miR-335 is downregulated
in peripheral blood mononuclear cells (PBMCs) and sera of
PD patients, while others have found increased levels of miR-
335 in PD serum samples (Yılmaz et al., 2016; Patil et al.,
2019; Oliveira et al., 2020). Importantly, some authors also
demonstrated that miR-335 upregulation reduces inflammation
and reactive oxygen species (ROS) in a sepsis mouse model (Gao
et al., 2018). In accordance, miR-335 downregulation appears
to affect mitochondrial dynamics, autophagy and apoptosis in
SH-SY5Y neuronal cells (De Luna et al., 2020). Interestingly,
in silico and in vitro studies point LRRK2 mRNA as a target of
this miRNA (Martins et al., 2011; Yılmaz et al., 2016; Patil et al.,
2019; Oliveira et al., 2020).
Thus, our main hypothesis is that miR-335 regulates key
inflammatory events by targeting LRRK2. In the present study,
we demonstrated that miR-335 is reduced in experimental models
of PD and in serum of idiopathic PD (iPD) and LRRK2-
associated PD (LRRK2-PD) patients vs. healthy individuals,
corroborating its clinical relevance during PD progression.
In addition, miR-335 overexpression protected microglial cells
from LPS-induced inflammation, by reducing RIP1 and RIP3
protein levels, proinflammatory cytokine expression and ERK1/2
activation. On a functional level, miR-335 directly targeted
LRRK2 and reduced wild-type LRRK2-driven inflammation. The
combination of novel miRNA strategies with LRRK2 inhibition
may translate into promising and innovative therapeutic
approaches to tackle PD.
MATERIALS AND METHODS
Cell Culture and Reagents
The BV2 and N9 murine microglial cell lines, kindly provided by
Elsa Rodrigues (University of Lisbon), were cultured in RPMI
1640 medium (GIBCO Life Technologies, Inc. Grand Island,
United States), supplemented with 10% heat inactivated fetal
bovine serum (FBS), 1% antibiotic/antimycotic solution and
1% GlutaMAXTM (GIBCO). The SH-SY5Y human inducible
WT α-synuclein (α-syn) cell line was cultured in RPMI 1640
medium, supplemented with 10% FBS, 1% penicillin (100 U/mL)
(GIBCO), 100 mg/mL streptomycin (GIBCO), 250 µg/mL G418
(Thermo Fisher Scientific, Rockford, IL, United States) and 50
µg/mL hygromycin B (Thermo Fisher). α-synuclein expression
was switched off by adding doxycycline (2 µg/mL) (Vekrellis
et al., 2009). Cells were maintained at 37◦C in a humidified
atmosphere of 5% CO2. LPS was from Escherichia coli 055:B5
(#437625; Calbiochem, San Diego, CA, United States).
MPTP Animal Model
Animal experiments were performed according to the animal
welfare organ of the Faculty of Pharmacy, University of Lisbon,
approved by the competent national authority Direção-Geral
de Alimentação e Veterinária (DAGV) and in accordance with
the EU Directive (2010/63/UE), Portuguese laws (DR 113/2013,
2880/2015, and 260/2016) and all relevant legislation. We
performed a sub-acute MPTP mouse model in 13-week-old
male C57BL/6N wild-type (Wt) obtained from the Charles
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River Laboratories (Wilmington, MA, United States). Mice were
intraperitoneally (i.p.) injected with a single dose of MPTP-
HCl (40 mg/kg; Sigma-Aldrich, St. Louis, MO, United States),
dissolved in sterile 0.9% saline, or vehicle only (control group);
seven animals per group were used (Saporito et al., 2000;
Dionísio et al., 2019). After 30 days, mice were sacrificed in a
CO2 chamber followed by transcardiac perfusion with ice-cold
phosphate buffered saline (PBS). Serum was collected and stored
at−80◦C.
miRNA Expression in Human Serum
We analyzed serum samples from 40 iPD, 41 LRRK2-PD patients
and 40 control individuals with no known neurological disorder
or family history of PD. Cases were selected from a randomized
cohort of 867 iPD patients included at the Movement Disorders
biobank (Instituto de Medicina Molecular, Lisbon, Portugal).
Healthy controls were selected from a randomized cohort of
287 individuals of the same biobank. The LRRK2-PD group
included 40 patients that carried the G2019S mutation and 5
patients that carried the R1441H mutation. All participants were
recruited at the Movement Disorders outpatient clinic of the
Hospital de Santa Maria (Lisbon, Portugal). Consent for inclusion
in the study was obtained before participation and the study was
performed in accordance with the Declaration of Helsinki and the
protocol approved by the Ethics Committee of Hospital de Santa
Maria. Serum isolation and miRNA extraction was performed
as previously reported (Oliveira et al., 2020). miRNA expression
was determined using TaqMan Universal Master Mix II no UNG
(Thermo Fisher Scientific) and the 7500 Sequence Detection
System (Applied Biosystems, Foster City, CA, United States),
according to the manufacturer’s recommendations. Relative miR-
335-3p expression levels of each subject were determined by
the comparative 11Ct method using the spike-in cel-miR-39-
3p (Thermo Fisher Scientific, Rockford, IL, United States) as
the normalization control. miR-335 expression levels of each PD
patient were normalized to the mean value of healthy controls.
Cell Transfection
BV2, N9, and SH-SY5Y cells were transfected with 40 nM
of a specific miR-335-3p precursor (pre-miR-335-3p; Ambion,
Thermo Fisher Scientific, Inc.) or a pre-miR negative control
(pre-miR-Control; Ambion, Thermo Fisher Scientific, Inc.) 24 h
after plating. To evaluate the targeting of LRRK2 by miR-
335-3p, BV2, and SH-SY5Y cells were co-transfected with
150 ng of a reporter plasmid driven by the SV40 basal
promotor, harboring the LRRK2 3′ untranslated region (UTR)
(HmiT002101-MT06, Tebu-bio, Lisbon, Portugal), or a negative
control region (CmiT000001-MT06, Tebu-bio), upstream of
the humanized firefly luciferase gene, in combination with
the pre-miR-335-3p/pre-miR-Control or anti-miR-335-3p/anti-
miR-Control (Ambion, Thermo Fisher Scientific, Inc.), for
24 h. For normalization, expression of the Renilla luciferase
gene, contained in the reported plasmid, was used. Reporter
assays were performed using Dual-Luciferase R© Reporter Assay
(Promega Corp.), according to the manufacturer’s instructions.
In LRRK2 overexpression experiments, BV2 or SH-SY5Y cells
were transfected with 500 ng of pDEST53-LRRK2-WT DNA
plasmid, gift from Mark Cookson (#25044, Addgene, Watertown,
MA, EUA) (Greggio et al., 2006) or empty-vector for 24 h,
before further treatments. Moreover, BV2 cells were transfected
with 250 ng of a plasmid encoding a constitutively active form
of mitogen-activated protein kinase (MEK1∗) (pCMB-deltaN3-
MEK1), kindly provided by Dr. Roger J. Davis (Howard Hughes
Medical Institute) or empty vector for 24 h before further
treatments. All transfections were performed with Lipofectamine
3000TM (Invitrogen, Thermo Fisher Scientific, Inc.), according to
the manufacturer’s recommendations.
Cell Viability/Death Assays
BV2 cells were plated in 96-well plates at 5 × 103 cells/well
and transfected the next day for 24 h before exposure to 100
ng/mL LPS for additional 24 h. SH-SY5Y cells, with or without
overexpression of α-syn, were plated in 96-well plates at 4 × 104
cells/well and transfected the next day for 24 h. Cellular metabolic
activity was determined using CellTiter 96 R© Aqueous Non-
Radioactive Cell Proliferation (MTS) Assay (Promega, Madison,
WI, United States). Alterations in absorbance were measured
at 490 nm using GloMax R© Multi Detection System (Sunnyvale,
CA, United States). Cell membrane integrity was determined
using the lactate dehydrogenase (LDH) Cytotoxicity KitPLUS
(Roche Diagnostics GmbH, Mannheim, Germany). Absorbance
was measured at 490 nm, with 620 nm reference wavelengths,
using a BioRad Model 680 microplate reader.
Protein Extraction and Immunoblotting
Analysis
BV2 and N9 cells were plated in 35-mm dishes at 1.1 × 105
cells/dish and transfected the next day for 24 h before treatment
with 100 ng/mL LPS for additional 24 h. SH-SY5Y cells, with
or without overexpression of α-syn, were plated in 35-mm
dishes at 12 × 105 cells/dish and transfected the next day for
24 h. Cells were collected in nonyl phenoxypolyethoxylethanol
(NP-40) lysis buffer [1% NP-40, 20 mM Tris–HCl pH 7.4,
150 mM NaCl, 5 mM EDTA, 10% glycerol, 1 mM dithiothreitol,
and 1x Halt Protease and Phosphatase Inhibitor Cocktail
EDTA-free (Pierce, Thermo Fisher Scientific, Rockford, IL,
United States)], followed by sonication and centrifugation at
3,200 g for 10 min at 4◦C. Total protein extracts were recovered
and stored at−80◦C. Protein concentration was calculated using
the colorimetric Bradford method (Bio-Rad), according to the
manufacturer’s recommendations. Equal amounts of protein (40
µg) were denatured and electrophoretically resolved on 6–8%
SDS-polyacrylamide gels and transferred onto nitrocellulose
membranes. Transient staining was performed with 0.2%
Ponceau S (Merck, Darmstadt, Germany) to confirm protein
loading and transfer. Membrane blocking was performed using
5% non-fat dried milk in Tris-buffered saline (TBS) for 1 h. Then,
membranes were incubated overnight at 4◦C with the following
primary rabbit antibodies: RIP1 (#3493, Cell Signaling, MA,
United States), RIP3 (#135170, Santa Cruz Biotechnology),
p-MLKL (Ser358) (#196436, Abcam; Cambridge, Unite
Kingdom), MLKL (#M6697, Sigma-Aldrich), IkB (#135170,
Santa Cruz Biotechnologies), p-p38 (Thr180/Tyr182) (#9211,
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Cell Signaling), Erk1/2 (#4695, Cell Signaling), and with the
following primary mouse monoclonal antibodies: JNK, p-JNK
(Thr183/Tyr185), p38α/β, p-Erk1/2 (Tyr204) (#7345, #6254,
#7972, #7383, Santa Cruz Biotechnologies) and p-IkB (Ser32/36)
(#9246, Cell Signaling) and LRRK2 (#133474, Abcam) and finally
with goat secondary antibodies conjugated with horseradish
peroxidase anti-mouse or anti-rabbit (Bio-Rad Laboratories,
Hercules, CA, United States) for 2 h at room temperature.
Membranes were then processed for protein detection using
ImmobilonTM Western (Merck Millipore, Burlington, MA,
United States) or SuperSignalTM West Femto Maximum
Sensitivity Substrate (Pierce, Thermo Fisher Scientific). β-Actin
(AC-15, Sigma Aldrich) was used as endogenous control.
Densitometric analysis was performed with the Image Lab
Software version 5.1 Beta (Bio-Rad).
Quantitative Real Time-PCR (qRT-PCR)
BV2 and N9 cells were plated in 12-well plates at 4 × 104
cells/well and transfected the next day for 24 h before treatment
with 100 ng/mL LPS for additional 24 h. SH-SY5Y cells, with
or without overexpression of α-syn, were plated in 12-well
plates at 5 × 105 cells/well and transfected in the following
day for 24 h. Total RNA was extracted using TRIzolTM reagent
(Invitrogen, Grand Island, United States) and quantified
using a QubitTM 2.0 fluorometer (Invitrogen). RNA was
then converted into cDNA using NZY Reverse Transcriptase
(NZYTech, Lisbon, Portugal). qRT-PCR was performed in
the QuantStudioTM 7 Flex Real-Time PCR System (Thermo
Fisher Scientific Inc.). The following primer sequences were
used: COX2 gene, 5′-CAGCCAGGCAGCAAATCCTT (forward)
and 5′-AGTCCGGGTACAGTCACACT (reverse); HPRT gene,
5′-GGTGAAAAGGACCTCTCGAAGTG (forward) and 5′-TA
GTCAAGGGCATATCCAACAACA (reverse); IL-1β gene, 5′-TG
CCACCTTTTGACAGTGATG (forward) and 5′-TGATGTGC
TGCTGCGAGATT (reverse); IL-6 gene, 5′-ATGAACTCCTTC
TCCACAAGC (forward) and 5′-GTTTTCTGCCAGTGCCTGT
TTG (reverse); NLRP3 gene, 5′-GAGCCTACAGTTG
GGTGAAATG (forward) and 5′-CCACGCCTACCAGGAAA
TCTC (reverse); and TNF-α gene, 5′-AGGCACTCCCC
CAAAAGATG (forward) and 5′-TGAGGGTCTGGGCCATA
GAA (reverse). Two independent reactions for each primer set
were performed in a final volume of 12.5 µL comprising 2x
Power SYBR green PCR master mix (Thermo Fisher Scientific,
Inc.) and 360 nM of each primer. The relative expression
levels of each gene of interest were determined based on the
standard curve normalized to the level of the housekeeping
gene hypoxanthine-guanine phosphoribosyltransferase (HPRT).
For miR-335-3p, TaqMan R© Gene Expression Assay (Thermo
Fisher Scientific, Inc.) was used. U6 or cel-miR-39-3p were used
as normalization control for cell extracts or serum samples,
respectively. Relative amount of miR-335-3p was calculated by
the threshold cycle (2−11Ct) method.
Statistical Analysis
Data analysis were performed with t-test and one-way analysis
of variance (ANOVA) followed by post hoc Bonferroni’s test.
Statistically significance was achieved when values of p < 0.05.
Analysis and graphical presentation were presented with the
GraphPad Prism software Version 8 (GraphPad Software
Inc., San Diego, CA, United States). Results are showed as
mean± standard error of the mean (SEM).
RESULTS
Patient Characterization
In this study, we included 40 iPD patients, 45 LRRK2-PD
patients and 40 age- and gender-matched healthy controls. The
major demographic and clinical features of patients and controls
are presented in Table 1. Of note, patients covering the full
spectrum of early to advanced PD, characterized by Hoehn and
Yahr stage (1–5) were included. Further, at the time of sample
collection, all patients were under treatment with antiparkinsonic
medication. Age and gender equilibrium were assured between
the three groups.
miR-335 Is Reduced in Experimental
Models of PD and in the Sera of PD
Patients
Recent studies have shown that the expression of miR-335 is
altered in PD (Martins et al., 2011; Patil et al., 2019; Oliveira
et al., 2020). Moreover, LRRK2 was pointed as a potential
target of miR-335 (Martins et al., 2011). Here, we decided to
further dissect the role of miR-335 in PD pathogenesis. We
started by analyzing the expression pattern of miR-335 in several
experimental models of PD. As an in vitro model of PD, we
used the BV2 murine microglia cell line transiently transfected
with a plasmid encoding wild-type LRRK2 (LRRK2-Wt), or
empty vector, followed by LPS stimulation. Our results showed
that LRRK2-Wt overexpression and/or cell incubation with
LPS for 24 h significantly reduced miR-335 expression levels
(Figure 1A). In vivo, we used 13-week-old male, injected
intraperitoneally with a single dose of MPTP, or vehicle, and
euthanized 30 days later, as a more clinically relevant model.
This PD mouse model displays stable nigrostriatal dopaminergic
neurodegeneration at 30 days, which is in accordance with
the notion that dopaminergic neurodegeneration in PD
patients majorly precedes the development of motor symptoms
(Saporito et al., 2000; Kordower et al., 2013; Dionísio et al., 2019).







Age (years) 67.4 ± 8.19 70.4± 10.2 70.0 ± 9.0
Gender (F/M) 20/20 20/20 31/14
Age at symptom onset (years) – 58.2± 12.7 56.4 ± 11.9
Disease duration (years) – 12.3 ± 9.1 13.6 ± 7.8
Hoehn and Yahr – 2.5 ± 0.9 2.7 ± 1.0
Family history of PD (%) – 35.0 63.4
Data are presented as mean ± standard deviation. iPD, idiopathic Parkinson’s
disease; LRRK2-PD, LRRK2 mutation Parkinson’s disease.
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FIGURE 1 | miR-335 is reduced in in vitro and in vivo experimental models of PD and in the sera PD patients. (A) qRT-PCR analysis of miR-335 in BV2 microglial
cells transfected with LRRK2-Wt overexpression plasmid, or empty vector, for 24 h and then stimulated with 100 ng/mL LPS for additional 24 h. (B) qRT-PCR
analysis of miR-335 in the sera of MPTP-injected mice or control mice, euthanized at 30 days after MPTP injection. Values were normalized to the mean of control
mice. (C) qRT-PCR analysis of miR-335 in serum of iPD and LRRK2-PD patients and control individuals. Values were normalized to the mean of control healthy
individuals. Results are expressed as mean ± SEM. ∗p < 0.05 vs. Control; p < 0.05 vs. control Empty vector.
We observed that MPTP-injected mice presented a significant
reduction of miR-335 in the serum, when compared to control
mice (Figure 1B). Finally, we determined the expression levels
of miR-335 in serum samples of 40 iPD patients, 41 LRRK2-PD
patients and 40 healthy controls, and confirmed that miR-335
was significantly reduced in the sera of iPD and LRRK2-PD
patients in comparison with control subjects (Figure 1C).
Although miR-335 levels were not significantly reduced in
iPD patients in comparison with LRRK2-PD patients, a slight
tendency of miR-335 to be reduced in iPD patients was observed,
which could suggest that the role of LRRK2 in reducing miR-335
levels contributes to PD pathology in combination with several
other mechanisms. Overall, these results indicate that miR-335 is
reduced both in vitro and in vivo experimental models of PD, and
most importantly, in the sera of PD patients, which highlights the
potential of modulating miR-335 to alleviate PD pathogenesis.
miR-335 Overexpression Reduces
LPS-Mediated RIP1 and RIP3 Increased
Levels
Emerging evidence suggest a role of miR-335 in regulating
inflammation in different experimental models of disease.
Moreover, several authors have proposed that key necroptosis
mediators such as RIP1 and RIP3 are involved in inflammatory
responses, especially in macrophages and microglia, without
necroptosis commitment (Christofferson et al., 2012; Ito
et al., 2016; Ofengeim et al., 2017; Degterev et al., 2019).
Here, to determine the involvement of RIP1 and RIP3 in
the inflammatory response, we used BV2 and N9 microglia
cells transfected with pre-miR-335, or pre-negative control
(NC), for 24 h, followed by stimulation with LPS for
additional 24 h; and SH-SY5Y neuroblastoma cells, with or
without α-syn overexpression, transfected with pre-miR-335
or NC for 24 h. In both microglia and neuroblastoma cells,
transfection with pre-miR-335 significantly increased miR-335
expression levels, thus confirming miRNA transfection efficiency
(Supplementary Figures 1A,B). In addition, as expected,
stimulation of BV2 cells with LPS or α-syn overexpression
in SH-SY5Y cells did not induce cell death in MTS and
LDH release assays (Supplementary Figures 1C,D). Similarly,
miR-335 overexpression did not affect cell viability in both
cell lines (Supplementary Figures 1C,D). However, LPS
stimulation in BV2 and N9 cells significantly increased RIP1
and RIP3 protein levels, thus indicating that LPS-induced
protein expression of RIP1 and RIP3 may be related to
inflammatory events (Figures 2A,B). Importantly, miR-335
overexpression per se did not influence RIP1 and RIP3 levels,
while concomitant LPS stimulation and miR-335 overexpression
significantly reduced LPS-induced RIP1 and RIP3 protein
expression, further suggesting a role for this miRNA in decreasing
inflammation (Figures 2A,B). In agreement, a marker of
necroptosis commitment such as the p-MLKL/MLKL ratio
showed no significant differences (Figures 2A,B). Moreover, no
differences were observed in RIP1 and RIP3 protein levels in BV2
cells overexpressing LRRK2-Wt (Supplementary Figure 2A). In
SH-SY5Y cells with or without α-syn overexpression and/or miR-
335 overexpression, no differences were observed in RIP1, RIP3,
and MLKL protein levels (Supplementary Figure 2B).
miR-335 Overexpression Attenuates
LPS- or α-Syn-Mediated Expression of
Proinflammatory Mediators and
LPS-Induced ERK1/2 Activation
Some authors have already proposed that miR-335
downregulation may have a deleterious effect by increasing the
production of proinflammatory mediators in an inflammatory
sepsis mouse model (Gao et al., 2018). To further determine
the role of miR-335 in modulating inflammatory events, BV2
and N9 microglia cells were transfected with a pre-miR-335
or NC for 24 h, and further incubated with LPS for additional
24 h. Similarly, SH-SY5Y neuroblastoma cells with or without
α-syn overexpression were transfected with a pre-miR-335
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FIGURE 2 | Modulation of LPS-induced protein expression of RIP1 and RIP3
by miR-335. BV2 microglial cells (A) and N9 microglial cells (B) were
transfected with pre-miR-335 or negative control (NC) for 24 h and then
stimulated with LPS for additional 24 h. Total protein extracts were prepared
for Western blot analysis of RIP1, RIP3, and p-MLKL/MLKL ratio.
Representative immunoblots are presented. β-Actin was used as loading
control. Values are expressed as mean ± SEM of three independent
experiments. *p < 0.05 vs. NC; }p < 0.05 vs. NC exposed to LPS.
or NC for 24 h. Our results demonstrated that incubation of
BV2 and N9 cells with LPS significantly increased TNF-α and
IL-1β; or TNF-α, IL-1β, COX2, and NLRP3 mRNA levels,
respectively (Figures 3A,B). No differences were observed in
COX2 and NLRP3 mRNA levels in BV2 cells exposed to LPS
(Figure 3A). As expected, miR-335 overexpression by itself
did not influence mRNA levels of these cytokines. However,
concomitant LPS incubation and miR-335 overexpression
significantly decreased the mRNA levels of proinflammatory
mediators (Figures 3A,B). In respect to neuronal cells, α-syn
overexpression in SH-SY5Y cells significantly increased TNF-α
and IL-6 mRNA levels, while no differences were observed in
COX2, thereby indicating an α-syn-dependent inflammatory
status in these cells (Figure 3C). Again, miR-335 overexpression
alone did not influence the expression of these proinflammatory
genes. However, when cells overexpress α-syn, miR-335 increased
levels significantly attenuate α-syn-induced TNF-α and IL-6
(Figure 3C). These results confirm the potential of miR-335 in
modulating inflammation in both neuronal and microglial cells.
Then, to further confirm mRNA proinflammatory gene
expression and dissect inflammatory signaling pathways
modulated by miR-335, we investigated the phosphorylation
states of JNK (Thr183/Tyr185), p38 (Thr180/Tyr182), and
ERK1/2 (Tyr204), three classic MAPK inflammatory signaling
pathways, as well as NF-κB activation, which is a key mediator
of inflammatory responses (Hashimoto et al., 2003; Tortarolo
et al., 2003; Liu et al., 2017), in BV2 cells exposed to LPS from
30 min up to 24 h. As depicted in Figure 4, ERK1/2 pathway was
activated at 4 and 6 h of LPS exposure (Figures 4A,B), but not at
earlier or later time points (data not shown), as determined by the
ratio between phosphorylated and total protein levels. Similarly,
NF-κB was strongly activated at 4 and 6 h post LPS, as indirectly
determined by the p-IκB/IκB ratio (Figures 4A,B). p38 and
JNK pathways showed no alterations (Figure 4A). Importantly,
transfection of cells with miR-335 alone did not activate
these signaling pathways; however, miR-335 overexpression
significantly reduced LPS-induced ERK1/2 and NF-κB activation
(Figures 4A,B). To further confirm that the observed decrease
in LPS-induced ERK1/2 levels is mediated by miR-335, we
determined proinflammatory mRNA levels in BV2 cells after
transfection with a plasmid encoding a constitutive active form
of MEK1 (MEK1∗), which is the upstream kinase of ERK1/2.
Our results showed that expression of MEK1∗ tended to abrogate
miR-335 effect, as observed by an increase in TNF-α and IL-1β
mRNA levels (Supplementary Figure 3).
miR-335 Directly Targets LRRK2 and Its
Overexpression Attenuates
LRRK2-Wt-Driven Inflammatory Events
Previous in silico studies have proposed LRRK2 as a putative
target of miR-335, which was further confirmed in vitro (Yılmaz
et al., 2016; Patil et al., 2019). Here, using dual-luciferase
assay and western blot analysis, we also confirmed that miR-
335 directly targets LRRK2 in both BV2 microglial and SH-
SY5Y neuroblastoma cells (Figures 5A–D). In addition, using
well-known in silico tools including TargetScan and PicTar
databases, we found that α-syn 3′-UTR is also a putative
target of miR-335 (Supplementary Figure 4). Although LRRK2
pathogenic mutations are linked to dopaminergic cell death,
there is also evidence suggesting that LRRK2-Wt overexpression
upregulates α-syn levels, thereby influencing the pathological
output of LRRK2-related PD (Lin et al., 2009; Carballo-
Carbajal et al., 2010). Here, we used BV2 microglial cells
co-transfected with LRRK2-Wt expression plasmid and pre-
miR-335, and further incubated with LPS for additional 24 h;
and SH-SY5Y neuroblastoma cells, with or without α-syn
overexpression co-transfected with LRRK2-Wt and pre-miR-335.
Transfection of BV2 cells with LRRK2-Wt plasmid resulted in
a significant increase of LRRK2 protein, which in turn was
attenuated by miR-335 overexpression (Figure 5D). Additionally,
LRRK2-Wt overexpression, with or without concomitant LPS
incubation, did not affect cell viability, as observed by MTS
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FIGURE 3 | Modulation of LPS or α-syn-mediated proinflammatory mRNA levels by miR-335. BV2 (A) and N9 (B) cells were transfected with a pre-miR-335 or
pre-NC for 24 h, and then stimulated with LPS for additional 24 h. (C) SH-SY5Y cells with or without overexpression of α-syn were transfected with a pre-miR-335
or pre-NC for 24 h. mRNA levels were measured by qRT-PCR. Results are expressed as mean ± SEM from three independent experiments. }p < 0.01 vs. NC;
*p < 0.05 vs. NC overexpressing α-syn or NC exposed to LPS.
and LDH assays (Supplementary Figure 5A). Also, miR-335
overexpression did not induce any alteration in cell viability,
in the presence or absence of LRRK2-Wt overexpression
(Supplementary Figure 5A). Similar results were observed
in SH-SY5Y cells with or without α-syn and concomitant
overexpression of LRRK2-Wt (Supplementary Figure 5B).
Finally, the role of LRRK2 in inflammation has been studied
since the identification of LRRK2 as one of the genes causing
susceptibility for the development of inflammatory diseases.
Moreover, recent evidence shows that LRRK2 is elevated in
immune cells, including microglia, where it may promote
inflammation (Gillardon et al., 2012; Moehle et al., 2012). Thus,
we wanted to explore whether LRRK2-Wt overexpression could
influence the expression of proinflammatory genes, which may
in turn be modulated by miR-335. We used BV2 microglia
cells co-transfected with LRRK2-Wt or empty vector plasmid
and pre-miR-335 for 24 h, and further incubated with LPS
for additional 24 h, or SH-SY5Y cells overexpressing α-syn co-
transfected with LRRK2-Wt or empty vector plasmid and pre-
miR-335 for 24 h. Here, LRRK2-Wt overexpression significantly
increased TNF-α, IL-1β and NLRP3 but not COX2 mRNA levels.
Concomitant treatment with LPS further increased the levels
of these proinflammatory markers (Figure 5E). Importantly,
miR-335 overexpression significantly reduced TNF-α and IL-
1β mRNA levels in both LRRK2-Wt and LRRK2-Wt exposed
to LPS conditions (Figure 5E). Similar results were observed
in SH-SY5Y cells, where LRRK2-Wt overexpression significantly
increased TNF-α, IL-1β and COX2 mRNA levels with or without
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FIGURE 4 | Modulation of ERK1/2 and NF-κB activation by miR-335. BV2 cells were transfected with a pre-miR-335 or pre-NC for 24 h and then stimulated with
LPS for 4 or 6 h. Representative immunoblots for p-ERK/ERK, p-JNK/JNK, p-p38/p38, and p-IκB/IκB ratios (A) and densitometric analysis of p-ERK/ERK and
p-IκB/IκB ratios (B) are presented. Results are presented as mean ± SEM of three independent experiments. *p < 0.0.5 vs. C 0 h; }p < 0.05 vs. LPS 4 h;
¥p < 0.05 vs. LPS 6 h.
α-syn overexpression (Figure 5F). More importantly, miR-335
overexpression also significantly decreased TNF-α and IL-1β
mRNA levels (Figure 5F). These results confirm the role of
miR-335 in protecting microglia and neuronal cells from an
inflammatory phenotype.
DISCUSSION
In this study, we hypothesized that miR-335 plays important roles
during inflammation by targeting LRRK2. We first determined
the levels of miR-335 in different in vitro models and its
circulating levels in in vivo PD-mimicking experimental models
and in PD patients. Recent studies have shown that miR-
335 may be linked to PD pathogenesis, since we and others
have found reduced expression levels in whole blood, PBMCs
and serum of PD patients compared with control subjects
(Martins et al., 2011; Yılmaz et al., 2016; Oliveira et al., 2020).
In accordance, here we observed that miR-335 is significantly
reduced in the sera of both iPD and LRRK2-PD patients as
compared with control subjects. Others have suggested that the
role of miR-335 in PD pathogenesis is mediated by LRRK2
(Yılmaz et al., 2016; Patil et al., 2019). In this regard, we
confirmed that miR-335 directly targets LRRK2 in BV2 and SH-
SY5Y cells. Moreover, it has been demonstrated that LRRK2
expression is induced by inflammatory stimuli, such as LPS
or IFN-γ in activated microglia, PBMCs and cultured bone
marrow-derived macrophages (Gardet et al., 2010; Hakimi
et al., 2011; Moehle et al., 2012). LRRK2 protein activation is
linked to inflammatory signaling, while no significant differences
occur in LRRK2 mRNA levels, which could suggest a post-
transcriptional regulation, for instance by miRNAs (Moehle
et al., 2012). Here, we showed that BV2 microglial cells
stimulated with LPS presented a significant reduction in miR-
335 expression levels. Moreover, concomitant overexpression
of LRRK2-Wt also contributed to a reduction in the levels
of this miRNA, which could indicate a feedback loop where
an inflammatory stimulus reduces miR-335 expression, which
may in turn promote an increase in LRRK2 protein levels,
therefore exacerbating inflammation. In fact, others have shown
that in response to TLR4 activation, LRRK2 inhibition, either
by small-molecule kinase inhibitors or LRRK2 knockdown,
reduces proinflammatory signaling pathways (Moehle et al.,
2012). Furthermore, we determined miR-335 expression levels
in the sera of mice subjected to a single injection of the MPTP
neurotoxin, a well-known trigger of PD-related pathology, and
observed that miR-335 was significantly reduced in these mice
in comparison with control mice, which may suggest an overall
reduction in miR-335 levels in the presence of an inflammatory
environment. Indeed, others have demonstrated that MPTP-
treated mice present increased expression of TLR4, which is
involved in the release of proinflammatory molecules from
microglia (Lofrumento et al., 2011; Shao et al., 2019). Overall,
these results suggest that the levels of miR-335 decrease in
response to inflammatory environments. Thus, it is possible to
speculate about the potential role of this miRNA in contributing
to an overall reduction of inflammation in animal models of
PD-related pathologies.
Considering that miR-335 is reduced in different
inflammatory PD models, we tested if elevating the levels
of miR-335 could impact on inflammation. Notably, we observed
that miR-335 overexpression significantly reduced RIP1 and
RIP3 protein levels induced by LPS stimulation in BV2 and
N9 microglial cells, while no differences were observed in
p-MLKL/MLKL ratio nor in cell viability, indicating that
modulation of RIP1/3 by miR-335 did not influence cell
death by necroptosis in these models. In fact, some studies
have demonstrated that proinflammatory stimulation of
macrophages and microglia and consequent RIP1 activation,
with or without RIP3 recruitment, could induce the expression
of proinflammatory genes, with no MLKL involvement or cell
death associated (Christofferson et al., 2012; Ito et al., 2016;
Ofengeim et al., 2017; Degterev et al., 2019). Interestingly,
no differences in RIP1 and RIP3 were observed in SH-SY5Y
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FIGURE 5 | MiR-335 directly targets LRRK2. (A) SH-SY5Y cells were co-transfected with a LRRK2 luciferase reporter vector, or negative control, and
pre-miR-335/pre-NC; or anti-miR-335/anti-NC for 24 h. (B) BV2 cells were co-transfected with a LRRK2 luciferase reporter vector, or negative control, and
pre-miR-335/pre-NC; or anti-miR-335/anti-NC for 24 h. Renilla luciferase signal was used as an internal standard control. Results are presented as mean ± SEM of
three independent experiments. *p < 0.0.5 vs. pre-NC. (C) Representative immunoblots are presented for LRRK2 in SH-SY5Y cells. β-Actin was used as loading
control. (D) BV2 cells were co-transfected with a LRRK2-Wt or empty vector plasmid and with a pre-miR-335 or pre-NC for 24 h, and then stimulated with LPS for
additional 24 h. Representative immunoblots are presented for LRRK2. β-Actin was used as loading control. (E) Modulation of LRRK2-Wt-induced proinflammatory
mRNA levels by miR-335. BV2 cells were co-transfected with a LRRK2-Wt or empty vector plasmid and with a pre-miR-335 or pre-NC for 24 h, and then stimulated
with LPS for additional 24 h. TNF-α, IL-1β, COX2, and NLRP3 mRNA levels were measured by qRT-PCR. Results are expressed as mean ± SEM from three
independent experiments. *p < 0.05 vs. empty vector; }p < 0.05 vs. empty vector transfected with pre-NC, p < 0.05 vs. LRRK2-Wt; p < 0.05 vs. LRRK2-Wt
exposed to LPS. (F) Modulation of LRRK2-Wt-induced proinflammatory mRNA levels by miR-335. SH-SY5Y cells with or without overexpression of α-syn were
co-transfected with a LRRK2-Wt or empty vector plasmid and with a pre-miR-335 or pre-NC for 24 h. TNF-α, IL-1β, and COX2 mRNA levels were measured by
qRT-PCR. Results are expressed as mean ± SEM from three independent experiments. *p < 0.05 vs. empty vector; }p < 0.05 vs. empty vector transfected with
pre-NC, **p < 0.05 vs. NC overexpressing α-syn; p < 0.05 vs. LRRK2-Wt without α-syn overexpression; p < 0.05 vs. LRRK2-Wt with α-syn overexpression.
cells overexpressing α-syn, thus suggesting that, at least in our
conditions, α-syn overexpression is not sufficient for inducing
inflammatory-dependent activation of RIP1 and RIP3, or that
the cells themselves may not rely as strongly on RIP1/3 signaling
as microglial cells. Importantly, LPS stimulation of BV2 and
N9 microglial cells as well as α-syn overexpression in SH-SY5Y
cells strongly induced the expression of several proinflammatory
genes, including TNF-α, IL-1β, IL-6, COX2, and NLRP3, which
was counteracted by miR-335 overexpression, thus highlighting
the role of miR-335 as an anti-inflammatory miRNA. These
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results are in accordance with other studies where miR-335
upregulation was associated with decreased inflammation
through the reduction of proinflammatory gene expression,
ROS levels and inflammasome activation in a sepsis mice model
(Gao et al., 2018). In SH-SY5Y cells, others also demonstrated
that miR-335 inhibition results in increased ROS production
(De Luna et al., 2020).
Throughout the years, several lines of evidence have proposed
that increased proinflammatory gene expression depends on
the activation of multiple MAPKs, specially p38, ERK1/2
and JNK, and downstream activation of transcription factors,
such as NF-κB. However, the precise mechanisms connecting
these events to RIP1 and/or RIP3 activation are still poorly
understood (Christofferson et al., 2012; Ito et al., 2016; Zhu et al.,
2018). Interestingly, some studies demonstrated that increased
LRRK2 protein levels promote ERK1/2 activation, without
affecting p38 or JNK signaling pathways (Carballo-Carbajal
et al., 2010). Our results are in accordance with these studies
since miR-335 overexpression reduced LPS-induced ERK1/2
activation, thereby confirming its role in reducing inflammation
which is probably mediated by LRRK2 inhibition. Overall,
we observed that stimulation of cells with a proinflammatory
stimulus, such as LPS, strongly increases RIP1 and RIP3
protein levels, which may consequently contribute to the
activation of ERK1/2 pathway, thus leading to the downstream
activation of NF-κB transcription factor, which may contribute
to the induction of proinflammatory gene expression (Festjens
et al., 2007; Humphries et al., 2015). Importantly, miR-335
demonstrated high anti-inflammatory potential by reducing
these inflammatory mechanisms.
After determining the role of miR-335 overexpression in
diminishing inflammation mediated by a classical inflammatory
stimulus, we hypothesized that miR-335 could also reduce
LRRK2-Wt-driven inflammation and/or cell death. LRRK2 has
been widely described in the regulation of several inflammatory
pathways and its activation associated with neuronal death
(Chen et al., 2012). Interestingly, although LRRK2 mutations are
commonly linked to neuronal death exacerbation, the role
of LRRK2-Wt overexpression is not completely understood,
with some studies showing a role in protecting SH-SY5Y
cells from death (Liou et al., 2008), and others indicating a
deleterious effect by increasing α-syn levels in HEK293 cells
(Carballo-Carbajal et al., 2010). Moreover, in both SH-SY5Y and
immune cells, LRRK2-Wt overexpression seems to have other
detrimental effects, including mitochondrial fragmentation and
inflammation (Marker et al., 2012; Moehle et al., 2012; Wang
et al., 2012; Berwick et al., 2019). Our results showed that
LRRK2-Wt overexpression did not induce cell death in BV2
nor SH-SY5Y cells. However, LRRK2-Wt overexpression strongly
induced proinflammatory gene expression in BV2 microglia and
SH-SY5Y neuroblastoma cells, while miR-335 overexpression
attenuated this effect.
In conclusion, we have unraveled a novel role for miR-335
during inflammation in PD-like conditions in both microglial
and neuronal cells, which are probably but not exclusively
dependent on LRRK2 targeting. Here, miR-335 showed to
be reduced in different in vitro and in vivo PD-mimicking
models and in PD patients, while its overexpression strongly
reduced inflammation induced by either LPS stimulation or
LRRK2-Wt overexpression. These observations suggest that miR-
335 overexpression may contribute to a less pro-inflammatory
activation in PD, thereby contributing to attenuate chronic
neuroinflammation and PD progression.
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